Navigation Links
CV Therapeutics Receives European Marketing Authorization for Ranolazine for the Treatment of Patients With Chronic Angina
Date:7/10/2008

PALO ALTO, Calif., July 10 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that it has received marketing authorization from the European Medicines Agency (EMEA) for ranolazine for the treatment of patients with chronic angina in all 27 European Union (EU) member states. This approval follows a positive opinion from the EMEA Committee for Medicinal Products for Human Use (CHMP) on April 24, 2008.

Ranolazine is approved for use in Europe as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies. Ranolazine is approved for use in 375 mg, 500 mg and 750 mg doses, administered twice daily.

The approved European labeling reflects data from the MERLIN TIMI-36 and other recently reported studies, including data showing statistically significant reductions in ventricular arrhythmias with ranolazine. The labeling also notes that the ability of ranolazine to reduce cellular calcium overload is expected to improve myocardial relaxation and decrease left ventricular diastolic stiffness.

"We expect ranolazine could be available to patients and physicians across Europe beginning in the first part of 2009, as we continue to see very strong interest from potential commercial partners," said Louis G. Lange, M.D., Ph.D., chairman and chief executive officer of CV Therapeutics. "Revenues from European sales of ranolazine would represent a fourth product-related revenue stream for CV Therapeutics."

There are currently 48-50 million angina prescriptions written annually in the largest five EU member countries (UK, Germany, France, Spain and Italy).

"Considering the well-established ne
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program
2. Arete Therapeutics Names James Sabry, M.D., Ph.D., President and Chief Executive Officer
3. Nabriva Therapeutics Announces Appointment of New CEO
4. Pearl Therapeutics Closes $18 Million Financing Round Led By Committed Investors
5. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
6. Joseph B. Bolen, Ph.D. from Millennium to Conference Chair Cancer Sessions at IBCs Drug Discovery & Development of Innovative Therapeutics Conference
7. Tobira Therapeutics Inc. Announces Senior Management Team
8. Duska Therapeutics Obtains Standard & Poors Listing
9. Spectral announces continuing support for the combination of EAA(TM) and anti-endotoxin therapeutics
10. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
11. Sirion Therapeutics Announces FDA Approval of Durezol(TM) for Treatment of Postoperative Ocular Inflammation and Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Mass. Using a bio-mimicking analog of one ... grass, an international research team led by Alejandro ... taken a major step in developing long-sought polymer ... electricity for use in electronic devices. , ... Amherst and others at Stanford University and Dresden ...
(Date:9/30/2014)... Shimadzu Scientific Instruments has released the ... precise tool for measuring displacement in rubber and ... maximum movement distance, the DSES-1000 can measure elongations ... of 10 mm. In addition, it achieves +/- ... and within +/- 100 µm below 50-mm stroke. ...
(Date:9/30/2014)... 30, 2014 Proove Biosciences , ... excited to announce a new genetic test built upon ... Pain Perception Test will provide physicians with an ... pain tolerance levels are stratified between individuals. With this ... a person has a genetic predisposition that will affect ...
(Date:9/30/2014)... Sept. 30, 2014 CORD:USE Cord Blood Bank ... that it has entered into an Equity and Exclusive ... has licensed a series of patented technologies for the isolation ... clinical applications.  Tianhe is performing Phase I/II clinical trials ... Spain using Tianhe,s Stem Cell Educator Therapy ...
Breaking Biology Technology:Blades of grass inspire advance in organic solar cells 2Blades of grass inspire advance in organic solar cells 3Shimadzu’s New Long-Travel Extensometer Increases Precision for Soft Material Testing 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 2CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 4
... (Amex: PLX ), announced today the pricing of ... stock at a,public offering price of $5.00 per share. ... to purchase up to 1,500,000 additional shares of,common stock ... is acting as sole book-running manager for this,offering. CIBC ...
... Oct. 24 , First Quarter Highlights:, - ... - Diluted EPS up 40% to $0.35 year-over-year, excluding ... related to one-time non-U.S. net tax adjustments PAREXEL ... results for the first quarter ended September 30, 2007. ...
... The Pittsburgh Life Sciences,Greenhouse (PLSG), the private/public ... a fast track for growth, announced that ... LLC, a developmental-stage,medical device company, whose goal ... probe that will alleviate the existing,limitations of ...
Cached Biology Technology:Protalix BioTherapeutics Announces Pricing of Public Offering of Common Stock 2PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results 2PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results 3PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results 4PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results 5PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results 6PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results 7PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results 8PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results 9The PLSG Invests $115,000 in Innovention Technologies, LLC 2
(Date:9/30/2014)... -- Pollution in urban and farm runoff in Hawaii ... study finds. , The study, published Tuesday in ... nitrogen in the runoff ends up in algae that ... the animals, eyes, flippers and internal organs. , Scientists ... National Oceanic and Atmospheric Administration (NOAA) conducted the study ...
(Date:9/30/2014)... report that a new class of chemical compounds ... They have also pinpointed the relevant target enzyme, ... , Researchers led by LMU,s Professor Angelika ... Universitt Mnchen have identified a class of chemicals ... fight against malignant tumors. The compound is itself ...
(Date:9/30/2014)... Here,s some hope: A new research report published in ... , explains how scientists developed a synthetic version ... embryo development in human and mouse eggs similar to ... cell during fertilization. , "We believe that the results ... our understanding of human fertilization by providing a precise ...
Breaking Biology News(10 mins):Pollution linked to lethal sea turtle tumors 2Pollution linked to lethal sea turtle tumors 3Cancer therapy: Driving cancer cells to suicide 2Synthetic sperm protein raises the chance for successful in vitro fertilization 2
... LANE, OKCorn gluten meal, a powdery byproduct of ... for use as an organic, non-selective preemergence or preplant-incorporated ... of Agriculture-Agricultural Research Service and Oklahoma State University recently ... applications on direct-seeded squash (Cucurbita pepo), and determined that ...
... entomologists will meet at the Hilton Waikoloa Village March 27-30, ... Region," the theme of this year,s Annual Meeting of the ... Each year, invasive species such as the coffee berry borer ... to Hawaiian crops. Members of the media are invited to ...
... cancer cells trigger a set of genes similar to those ... Research in Biomedicine (IRB Barcelona) have found. The team of ... with colorectal cancer undergo genetic tests of their intestinal epithelium ... results of the study, published online this week in ...
Cached Biology News:Corn gluten meal tested on squash survival, yields 2Insect scientists battle invasive species in Hawaii 2Stem cells may be key to understanding the origins of colon cancer and detecting relapse 2
... Last innovation from Magnetofection technology, SilenceMag ... system available. Simple, rapid and easy ... and non toxic. Specifically designed for ... silencing at very low doses of ...
... Last innovation from Magnetofection technology, ... delivery system available. Simple, rapid and ... compatible and non toxic. Specifically designed ... gene silencing at very low doses ...
... Fluorescence Test Plate consists of an anodized ... Inert Organic Fluorescent Compounds embedded in polymerized ... on BioTeks FLx800 and Synergy Multi-Detection Readers. ... GLP compliance while reducing the need for ...
... Agarose and SYBR Safe DNA Gel Stain combo offers ... versus buying these same products separately ... ethidium bromide Eliminates risks ... DNA and RNA fragments from 100 bp to >30 ...
Biology Products: